Access to Medicine Index: Novartis first, Abbvie last

The breaks down the report's company rankings, highlighting companies that rose in the ranking and those that fell. 

It also highlights the report's finding that access plans now exist for 69% of candidate drugs in the final development phase, more than three times as many as in 2018. 

Marijn Verhoef, Director of Private Sector Engagement at the Access to Medicine Foundation is quoted: Setting goals to get expensive medicines to patients quickly in these regions as well was not a priority for most pharmaceutical executives twenty years ago. That has really changed.”